Combination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

MYC, a gene with high cancer-initiating potential, is overexpressed in over 40% of breast cancers.
While MYC programs breast cancer cells to build more macromolecules (anabolic metabolism), it also creates a metabolic vulnerability by making them more sensitive to a type of cell death known as apoptosis. Research Director Juha Klefstrom, PhD, University of Helsinki, Finland, has worked for a long time to exploit this apoptosis-sensitising effect of MYC in the battle against the cancer.

Read More